Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (R01AI137093, R01AI137093, R01AI137093)
National Center for Advancing Translational Sciences (UL1TR000142)
Received: 26 May 2022
Accepted: 20 September 2022
First Online: 25 October 2022
: The analysis of the data was approved by the Human Investigation Committees at Yale University.
: Not applicable.
: VEP has received reimbursement from Merck and Pfizer for travel expenses to Scientific Input Engagements on respiratory syncytial virus. DMW has received consulting fees from Pfizer, Merck, GSK, Affinivax, and Matrivax for work unrelated to this manuscript and is Principal Investigator on research grants from Pfizer and Merck on work unrelated to this manuscript. ZZ is expected to receive consulting fees from Pfizer. All other authors report no relevant conflicts.